Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label study of zilovertamab vedotin in relapsed or refractory diffuse large B-cell lymphoma
MOH_2022-01-05_010513Phase 2Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Oct 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zilovertamab vedotin in diffuse large B-cell lymphoma (DLBCL), sponsored by Merck & Co. Primary endpoint: Objective response rate. Started Oct 2021; status: active, not recruiting.
02
Drugs
zilovertamab vedotin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on MOH_2022-01-05_010513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-01-05_010513.